+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Crohn's Disease Forecast and Market Analysis to 2026

  • ID: 4238685
  • Report
  • August 2018
  • Region: Global
  • 679 Pages
  • Pharma Intelligence
The Number of Prevalent Cases of Crohn's Disease ss Expected to Increase by 16.9% to 1.6 Million over 2015-35
Disease Overview
Crohn’s disease involves inflammation of the gastrointestinal (GI) tract, and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of the GI tract, disease activity and severity can vary widely over time, with symptoms ranging from mild to severe and depending on the location in the GI tract at which the disease is active. Crohn’s disease is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood.

Market Snapshot
  • Stelara is set to become the leading brand in Crohn’s disease as the long-standing anti-TNFs face biosimilar competition.
  • Infliximab – Remicade and its biosimilar versions – remains the most frequently prescribed biologic by surveyed physicians.
  • Crohn’s disease is an expanding global health problem, with prevalent cases forecasted to increase worldwide.
  • Gastroenterologists intend to prescribe Stelara over Entyvio due to its faster onset of action and comparable safety.
  • Gastroenterologists remain skeptical about the JAK inhibitors as more data are needed to assess their risk/benefit profile.
  • Pipeline therapies will temper cost savings from anti-TNF biosimilars.
Note: Product cover images may vary from those shown
FORECAST: CROHN’S DISEASE
Overview
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology

BIBLIOGRAPHY
Product Profile: Alofisel
Product Profile: Cimzia
Product Profile: Entyvio
Product Profile: Humira
Product Profile: Remicade
Product Profile: Stelara
Product Profile: Tysabri
Product Profile: Etrolizumab
Product Profile: Filgotinib
Product Profile: Ozanimod
Product Profile: Risankizumab
Product Profile: Upadacitinib

TREATMENT: CROHN’S DISEASE
Overview
Executive Summary
Primary Research Methodology
Patient Segmentation
Current Treatment Options
Prescribing Trends
Compliance
Unmet Needs In Crohn’S Disease
Prescribing Influences
Impact Of Biosimilars

EPIDEMIOLOGY: CROHN’S DISEASE
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: CROHN'S DISEASE
Overview
Product Overview
Product Profile: Alofisel
Product Profile: Cimzia
Product Profile: Entyvio
Product Profile: Humira
Product Profile: Remicade
Product Profile: Stelara
Product Profile: Tysabri

CROHN'S DISEASE AND ULCERATIVE COLITIS PRICING AND REIMBURSEMENT
Overview
Executive Summary
Regulatory Labels
Global Access Levers
Evidence And Value
Access To Recently Approved And Pipeline Products
Pricing
Us
Japan
Biosimilar Tnf-Alpha Inhibitors In The Five Major Eu Markets
France
Germany
Italy
Spain
Uk
Methodology

PIPELINE: CROHN’S DISEASE
Overview
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile: Etrolizumab
Product Profile: Filgotinib
Product Profile: Ozanimod
Product Profile: Risankizumab
Product Profile: Upadacitinib

LIST OF FIGURES
Figure 1: Crohn’s disease – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for Crohn’s disease
Figure 3: Crohn’s disease sales across the US, Japan, and five major EU markets, by country, 2016–25
Figure 4: Crohn’s disease sales across the US, Japan, and five major EU markets, by class, 2016–25
Figure 5: Sales of Humira, Remicade, and their biosimilar versions across the US, Japan, and five major EU markets, 2016–25
Figure 6: Sales of Stelara, key branded anti-TNFs, and Entyvio across the US, Japan, and five major EU markets, by drug, 2016–25
Figure 7: Sales of filgotinib and upadacitinib across the US, Japan, and five major EU markets, by drug, 2016–25
Figure 8: Sales of risankizumab versus pipeline agents in the US, Japan, and five major EU markets, by drug, 2016–25
Figure 9: The authors Crohn’s disease forecast methodology
Figure 10: Price sources and calculations, by country
Figure 11: Alofisel for Crohn’s disease – SWOT analysis
Figure 12: The authors drug assessment summary of Alofisel in Crohn’s disease
Figure 13: The authors drug assessment summary of Alofisel in Crohn’s disease
Figure 14: Alofisel sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 15: Cimzia for Crohn’s disease – SWOT analysis
Figure 16: The authors drug assessment summary of Cimzia in Crohn’s disease
Figure 17: The authors drug assessment summary of Cimzia in Crohn’s disease
Figure 18: Cimzia sales for Crohn’s disease across the US, Japan, and Spain, by country, 2016–25
Figure 19: Entyvio for Crohn’s disease – SWOT analysis
Figure 20: The authors drug assessment summary of Entyvio in Crohn’s disease
Figure 21: The authors drug assessment summary of Entyvio in Crohn’s disease
Figure 22: Entyvio sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 23: Humira for Crohn’s disease – SWOT analysis
Figure 24: The authors drug assessment summary of Humira in Crohn’s disease
Figure 25: The authors drug assessment summary of Humira in Crohn’s disease
Figure 26: Humira sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 27: Remicade for Crohn’s disease – SWOT analysis
Figure 28: The authors drug assessment summary of Remicade in Crohn’s disease
Figure 29: The authors drug assessment summary of Remicade in Crohn’s disease
Figure 30: Remicade sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 31: Stelara for Crohn’s disease – SWOT analysis
Figure 32: The authors drug assessment summary of Stelara in Crohn’s disease
Figure 33: The authors drug assessment summary of Stelara in Crohn’s disease
Figure 34: Stelara sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 35: Tysabri for Crohn’s disease – SWOT analysis
Figure 36: The authors drug assessment summary of Tysabri in Crohn’s disease
Figure 37: The authors drug assessment summary of Tysabri in Crohn’s disease
Figure 38: Tysabri sales for Crohn’s disease in the US, 2016–25
Figure 39: Etrolizumab for Crohn’s disease – SWOT analysis
Figure 40: The authors drug assessment summary of etrolizumab in Crohn’s disease
Figure 41: The authors drug assessment summary of etrolizumab in Crohn’s disease
Figure 42: Etrolizumab sales for Crohn’s disease across the US and five major EU markets, by country, 2016–25
Figure 43: Filgotinib for Crohn’s disease – SWOT analysis
Figure 44: The authors drug assessment summary of filgotinib in Crohn’s disease
Figure 45: The authors drug assessment summary of filgotinib in Crohn’s disease
Figure 46: Filgotinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 47: Ozanimod for Crohn’s disease – SWOT analysis
Figure 48: The authors drug assessment summary of ozanimod in Crohn’s disease
Figure 49: The authors drug assessment summary of ozanimod in Crohn’s disease
Figure 50: Ozanimod sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 51: Risankizumab for Crohn’s disease – SWOT analysis
Figure 52: The authors drug assessment summary of risankizumab in Crohn’s disease
Figure 53: The authors drug assessment summary of risankizumab in Crohn’s disease
Figure 54: Risankizumab sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 55: Upadacitinib for Crohn’s disease – SWOT analysis
Figure 56: The authors drug assessment summary of upadacitinib in Crohn’s disease
Figure 57: The authors drug assessment summary of upadacitinib in Crohn’s disease
Figure 58: Upadacitinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 59: Severity of diagnosed Crohn’s disease patients, by country
Figure 60: Mean percentage of Crohn’s disease patients receiving pharmacological therapy or non-pharmacological therapy only, by country
Figure 61: Mean percentage use of systemic and non-systemic corticosteroids in the US, Japan, and five major EU markets, by line of therapy
Figure 62: Mean percentage of drug-treated Crohn’s disease patients receiving monotherapy versus combination therapy, by line of therapy
Figure 63: Mean percentage of drug-treated Crohn’s disease patients receiving anti-TNF therapy, by country and line of therapy
Figure 64: Mean percentage use of biologic therapies for the treatment of drug-treated Crohn’s disease patients, by biologic and line of therapy
Figure 65: Mean compliance rates for drug-treated Crohn’s disease patients, by formulation type
Figure 66: Top treatment challenges in Crohn’s disease
Figure 67: Summary of future usage of biosimilar infliximab at one year and three years post-launch
Figure 68: Physician confidence in prescribing biosimilars for Crohn’s disease approved on the basis of indication extrapolation, by country
Figure 69: Trends in diagnosed prevalent cases of Crohn’s disease in the US, Japan, and five major EU markets, by country, 2017–37
Figure 70: Alofisel for Crohn’s disease – SWOT analysis
Figure 71: The authors drug assessment summary of Alofisel in Crohn’s disease
Figure 72: The authors drug assessment summary of Alofisel in Crohn’s disease
Figure 73: Alofisel sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 74: Cimzia for Crohn’s disease – SWOT analysis
Figure 75: The authors drug assessment summary of Cimzia in Crohn’s disease
Figure 76: The authors drug assessment summary of Cimzia in Crohn’s disease
Figure 77: Cimzia sales for Crohn’s disease across the US, Japan, and Spain, by country, 2016–25
Figure 78: Entyvio for Crohn’s disease – SWOT analysis
Figure 79: The authors drug assessment summary of Entyvio in Crohn’s disease
Figure 80: The authors drug assessment summary of Entyvio in Crohn’s disease
Figure 81: Entyvio sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 82: Humira for Crohn’s disease – SWOT analysis
Figure 83: The authors drug assessment summary of Humira in Crohn’s disease
Figure 84: The authors drug assessment summary of Humira in Crohn’s disease
Figure 85: Humira sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 86: Remicade for Crohn’s disease – SWOT analysis
Figure 87: The authors drug assessment summary of Remicade in Crohn’s disease
Figure 88: The authors drug assessment summary of Remicade in Crohn’s disease
Figure 89: Remicade sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 90: Stelara for Crohn’s disease – SWOT analysis
Figure 91: The authors drug assessment summary of Stelara in Crohn’s disease
Figure 92: The authors drug assessment summary of Stelara in Crohn’s disease
Figure 93: Stelara sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 94: Tysabri for Crohn’s disease – SWOT analysis
Figure 95: The authors drug assessment summary of Tysabri in Crohn’s disease
Figure 96: The authors drug assessment summary of Tysabri in Crohn’s disease
Figure 97: Tysabri sales for Crohn’s disease in the US, 2016–25
Figure 98: Price sources and calculations for the US and EU, by country
Figure 99: Etrolizumab for Crohn’s disease – SWOT analysis
Figure 100: The authors drug assessment summary of etrolizumab in Crohn’s disease
Figure 101: The authors drug assessment summary of etrolizumab in Crohn’s disease
Figure 102: Etrolizumab sales for Crohn’s disease across the US and five major EU markets, by country, 2016–25
Figure 103: Filgotinib for Crohn’s disease – SWOT analysis
Figure 104: The authors drug assessment summary of filgotinib in Crohn’s disease
Figure 105: The authors drug assessment summary of filgotinib in Crohn’s disease
Figure 106: Filgotinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 107: Ozanimod for Crohn’s disease – SWOT analysis
Figure 108: The authors drug assessment summary of ozanimod in Crohn’s disease
Figure 109: The authors drug assessment summary of ozanimod in Crohn’s disease
Figure 110: Ozanimod sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 111: Risankizumab for Crohn’s disease – SWOT analysis
Figure 112: The authors drug assessment summary of risankizumab in Crohn’s disease
Figure 113: The authors drug assessment summary of risankizumab in Crohn’s disease
Figure 114: Risankizumab sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Figure 115: Upadacitinib for Crohn’s disease – SWOT analysis
Figure 116: The authors drug assessment summary of upadacitinib in Crohn’s disease
Figure 117: The authors drug assessment summary of upadacitinib in Crohn’s disease
Figure 118: Upadacitinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES
Table 1: Exchange rates used for calculating prices
Table 2: Gastroenterologists surveyed for the Crohn’s disease primary research study, 2016
Table 3: Alofisel drug profile
Table 4: Alofisel Phase III data in Crohn’s disease
Table 5: Alofisel Phase III trial in Crohn’s disease
Table 6: Alofisel Phase I/II data in Crohn’s disease
Table 7: Alofisel sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 8: Cimzia drug profile
Table 9: Cimzia pivotal trial data in Crohn’s disease
Table 10: Cimzia late-phase trial data in Crohn’s disease
Table 11: Cimzia sales for Crohn’s disease across the US, Japan, and Spain, by country, 2016–25
Table 12: Entyvio drug profile
Table 13: Entyvio pivotal trial data in Crohn’s disease
Table 14: Entyvio ongoing late-phase trials in Crohn’s disease
Table 15: Entyvio sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 16: Humira drug profile
Table 17: Humira pivotal trial data in adult Crohn’s disease
Table 18: Humira pivotal trial data in pediatric Crohn’s disease
Table 19: Humira ongoing trials in Crohn’s disease
Table 20: Humira sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 21: Remicade drug profile
Table 22: Remicade pivotal trial data in adult Crohn’s disease
Table 23: Remicade pivotal trial data in pediatric Crohn’s disease
Table 24: Remicade sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 25: Stelara drug profile
Table 26: Stelara pivotal trial data in Crohn’s disease
Table 27: Stelara sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 28: Tysabri drug profile
Table 29: Tysabri pivotal trial data in Crohn’s disease
Table 30: Tysabri sales for Crohn’s disease in the US, 2016–25
Table 31: Etrolizumab drug profile
Table 32: Ongoing pivotal trials for etrolizumab in Crohn’s disease
Table 33: Other late-phase trials for etrolizumab in Crohn’s disease
Table 34: Etrolizumab sales for Crohn’s disease across the US and five major EU markets, by country, 2016–25
Table 35: Filgotinib drug profile
Table 36: Ongoing pivotal Phase III trials of filgotinib in Crohn’s disease
Table 37: Phase II trial data of filgotinib in Crohn’s disease
Table 38: Filgotinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 39: Ozanimod drug profile
Table 40: Ozanimod Phase III trials in Crohn’s disease
Table 41: Ozanimod Phase II data in Crohn’s disease
Table 42: Ozanimod sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 43: Risankizumab drug profile
Table 44: Risankizumab Phase III trials in Crohn’s disease
Table 45: Risankizumab Phase II data in Crohn’s disease
Table 46: Risankizumab sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 47: Upadacitinib drug profile
Table 48: Upadacitinib Phase III trials in Crohn’s disease
Table 49: Upadacitinib Phase II data in Crohn’s disease
Table 50: Upadacitinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 51: Gastroenterologists surveyed for the Crohn’s disease primary research study, 2016
Table 52: Treatment guidelines: initial treatment of active Crohn’s disease, by severity
Table 53: Treatment guidelines: maintenance of medically induced remission of Crohn’s disease and other therapy recommendations
Table 54: Summary of key classes and products included in The authors Crohn’s disease survey
Table 55: Crohn’s disease patients receiving pharmacological therapy or non-pharmacological therapy only, by country
Table 56: Mean percentage of drug-treated Crohn’s disease patients receiving each drug class, by line of therapy and country
Table 57: Mean percentage of drug-treated Crohn’s disease patients receiving monotherapy or combination therapy, by line of therapy and country
Table 58: Mean percentage of drug-treated Crohn’s disease patients receiving each biologic therapy, by line of therapy and country
Table 59: Compliance rates for Crohn’s disease patients, by formulation type and country
Table 60: Relative importance of treatment challenges in Crohn’s disease, by country
Table 61: Relative importance of factors that influence gastroenterologists’ prescription of biologics and aminosalicylates in Crohn’s disease, by country
Table 62: Initial usage of biosimilar infliximab, according to respondents using biosimilar infliximab at the time of the survey, by country
Table 63: Expected usage of biosimilar infliximab, according to respondents who did not prescribe biosimilar infliximab at the time of the survey, by country
Table 64: Inflammatory bowel disease risk factors
Table 65: Montreal classification of Crohn’s disease
Table 66: Sources used for Crohn’s disease analysis in the US, Japan, and five major EU markets
Table 67: Crohn’s disease data processing methods in the US, Japan, and five major EU markets
Table 68: Diagnosed prevalent cases of Crohn’s disease in the US, Japan, and five major EU markets, by country, 2017–37
Table 69: Profiled key marketed drugs for Crohn’s disease
Table 70: Alofisel drug profile
Table 71: Alofisel Phase III data in Crohn’s disease
Table 72: Alofisel Phase III trial in Crohn’s disease
Table 73: Alofisel Phase I/II data in Crohn’s disease
Table 74: Alofisel sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 75: Cimzia drug profile
Table 76: Cimzia pivotal trial data in Crohn’s disease
Table 77: Cimzia late-phase trial data in Crohn’s disease
Table 78: Cimzia sales for Crohn’s disease across the US, Japan, and Spain, by country, 2016–25
Table 79: Entyvio drug profile
Table 80: Entyvio pivotal trial data in Crohn’s disease
Table 81: Entyvio ongoing late-phase trials in Crohn’s disease
Table 82: Entyvio sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 83: Humira drug profile
Table 84: Humira pivotal trial data in adult Crohn’s disease
Table 85: Humira pivotal trial data in pediatric Crohn’s disease
Table 86: Humira ongoing trials in Crohn’s disease
Table 87: Humira sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 88: Remicade drug profile
Table 89: Remicade pivotal trial data in adult Crohn’s disease
Table 90: Remicade pivotal trial data in pediatric Crohn’s disease
Table 91: Remicade sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 92: Stelara drug profile
Table 93: Stelara pivotal trial data in Crohn’s disease
Table 94: Stelara sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 95: Tysabri drug profile
Table 96: Tysabri pivotal trial data in Crohn’s disease
Table 97: Tysabri sales for Crohn’s disease in the US, 2016–25
Table 98: Marketed products and approved indications for Crohn’s disease drugs in the US, Japan, and five major EU markets
Table 99: Marketed products and approved indications for ulcerative colitis drugs in the US, Japan, and five major EU markets
Table 100: Levers impacting access to IBD drugs in the US and five major EU markets, by country
Table 101: Pricing of key Crohn’s disease drugs in the US, Japan, and five major EU markets, by country
Table 102: Pricing of key ulcerative colitis drugs in the US, Japan, and five major EU markets, by country
Table 103: Top anti-inflammatory drug prescriptions filled by Medicare beneficiaries participating in Part B and D programs, 2015
Table 104: Specialty drug spend by Express Scripts commercial members, 2016
Table 105: CVS Caremark and Express Scripts’ formulary exclusions for IBD drugs, 2016–18
Table 106: Formulary placement of IBD medications in selected commercial formularies
Table 107: Formulary placement of IBD medications in selected Medicare formularies
Table 108: Selected formulary practices of top 10 Medicare Part D and Medicare Advantage IBD drugs
Table 109: Formulary placement of IBD medications in selected state Medicaid formularies
Table 110: Prior authorization criteria for Crohn’s disease drugs with major health insurers and pharmacy benefit managers
Table 111: Prior authorization criteria for ulcerative colitis drugs with major health insurers and pharmacy benefit managers
Table 112: Japan – pricing premiums given to medicines that can demonstrate benefit over comparators
Table 113: Market access tools used to promote biosimilar TNF-alpha inhibitor uptake in the five major EU markets, by country
Table 114: Transparency Committee’s ASMR ratings and pricing implications
Table 115: Transparency Committee's SMR ratings and pricing implications
Table 116: Transparency Commission's assessment of Crohn’s disease treatments
Table 117: Transparency Commission's assessment of ulcerative colitis treatments
Table 118: G-BA assessment of key Crohn’s disease therapies
Table 119: G-BA assessment of key ulcerative colitis therapies
Table 120: Spending regulations for TNF-alpha inhibitors in the five largest physicians’ associations in Germany
Table 121: Reimbursement conditions for Crohn’s disease treatments in Italy
Table 122: Reimbursement conditions for ulcerative colitis treatments in Italy
Table 123: Italian regional formulary decisions for Crohn’s disease drugs
Table 124: Italian regional formulary decisions for ulcerative colitis drugs
Table 125: Therapeutic positioning reports for IBD drugs in Spain
Table 126: Spanish Society of Hospital Pharmacy ratings
Table 127: Regional MADRE assessments for Crohn’s disease drugs
Table 128: Regional MADRE assessments for ulcerative colitis drugs
Table 129: NICE assessments of key Crohn’s disease therapies
Table 130: NICE assessments of key ulcerative colitis therapies
Table 131: Exchange rates used for calculating drug prices
Table 132: Profiled pipeline products in development for Crohn’s disease
Table 133: Etrolizumab drug profile
Table 134: Ongoing pivotal trials for etrolizumab in Crohn’s disease
Table 135: Other late-phase trials for etrolizumab in Crohn’s disease
Table 136: Etrolizumab sales for Crohn’s disease across the US and five major EU markets, by country, 2016–25
Table 137: Filgotinib drug profile
Table 138: Ongoing pivotal Phase III trials of filgotinib in Crohn’s disease
Table 139: Phase II trial data of filgotinib in Crohn’s disease
Table 140: Filgotinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 141: Ozanimod drug profile
Table 142: Ozanimod Phase III trials in Crohn’s disease
Table 143: Ozanimod Phase II data in Crohn’s disease
Table 144: Ozanimod sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 145: Risankizumab drug profile
Table 146: Risankizumab Phase III trials in Crohn’s disease
Table 147: Risankizumab Phase II data in Crohn’s disease
Table 148: Risankizumab sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Table 149: Upadacitinib drug profile
Table 150: Upadacitinib Phase III trials in Crohn’s disease
Table 151: Upadacitinib Phase II data in Crohn’s disease
Table 152: Upadacitinib sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
Note: Product cover images may vary from those shown
Adroll
adroll